[Regulation of p53 function and promoter selectivity by post-translational modifications].
Tanaka
Tomoaki
T
Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.
D000107:Acetylation; D000595:Amino Acid Sequence; D000818:Animals; D029563:Cellular Apoptosis Susceptibility Protein / Q000502:physiology; D042002:Chromatin Assembly and Disassembly; D004247:DNA / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000235:genetics; D006801:Humans; D008969:Molecular Sequence Data; D009687:Nuclear Proteins / Q000235:genetics; D010766:Phosphorylation; D011485:Protein Binding; D011499:Protein Processing, Post-Translational; D055550:Protein Stability; D051736:Proto-Oncogene Proteins c-mdm2 / Q000502:physiology; D015534:Trans-Activators / Q000235:genetics; D014157:Transcription Factors; D014158:Transcription, Genetic / Q000235:genetics*; D000072160:Tumor Protein p73; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism / Q000502:physiology*; D025521:Tumor Suppressor Proteins / Q000235:genetics; D054875:Ubiquitination
D029563:Cellular Apoptosis Susceptibility Protein; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; C115051:TP63 protein, human; D015534:Trans-Activators; D014157:Transcription Factors; D000072160:Tumor Protein p73; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; D004247:DNA; D051736:Proto-Oncogene Proteins c-mdm2